You are here

Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults

Last updated on November 21, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
New Haven, Connecticut, 06511-5473 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Respiratory Tract Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Volunteers willing and able to be confined to the Clinical Research Unit and comply
with study schedule.

- Women of non-childbearing potential only.

- Japanese subjects muct have 4 Japanese grandparents who were born in Japan.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Previous antibiotic use within 14 days prior to dosing.

- Use of antibiotics during hospitalization within 90 days prior to dosing.

- History of sensitivity to macrolides or ketolides.

- Presence of clinically significant eye conditions (other than corrective lenses).

NCT00793000
Pfizer
Completed
Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults
Official Title  ICMJE A Phase 1 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04287881 After First Time Administration Of Ascending Single Oral Doses To Healthy Adult Subjects
Brief SummaryThe purpose of this study is to determine the safety, tolerability and pharmacokinetics of PF-04287881 after a single oral dose in healthy adult volunteers.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Condition  ICMJE Respiratory Tract Infections
Intervention  ICMJE
  • Drug: PF-04287881
    75 mg oral dose (prepared solution) given once
  • Drug: Placebo
    placebo to match 75 mg oral dose (prepared solution), given once
  • Drug: PF-04287881
    150 mg oral dose (prepared solution) given once
  • Drug: Placebo
    placebo to match 150 mg oral dose (prepared solution), given once
  • Drug: PF-04287881
    300 mg oral dose (prepared solution) given once
  • Drug: Placebo
    placebo to match 300 mg oral dose (prepared solution), given once
  • Drug: PF-04287881
    750 mg oral dose (prepared solution) given once
  • Drug: Placebo
    placebo to match 750 mg oral dose (prepared solution), given once
  • Drug: PF-04287881
    1000 mg oral dose (prepared solution) given once
  • Drug: Placebo
    placebo to match 1000 mg oral dose (prepared solution), given once
  • Drug: PF-04287881
    1250 mg oral dose (prepared solution) given once
  • Drug: Placebo
    placebo to match 1250 mg oral dose (prepared solution), given once
  • Drug: PF-04287881
    1500 mg oral dose (prepared solution) given once
  • Drug: Placebo
    placebo to match 1500 mg oral dose (prepared solution), given once
  • Drug: PF-04287881
    1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once
Study Arms  ICMJE
  • Experimental: Cohort 1
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 2
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 3
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 4
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 5
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 6
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 7
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 8
    Japanese volunteers, low dose previously tested (based on PK)
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 9
    Japanese volunteers, intermediate dose previously tested (based on PK)
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
  • Experimental: Cohort 10
    Japanese volunteers, high dose previously tested (based on safety)
    Interventions:
    • Drug: PF-04287881
    • Drug: Placebo
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 30, 2009)
80
Original Estimated Enrollment  ICMJE
 (submitted: November 17, 2008)
72
Actual Study Completion Date  ICMJE December 2009
Actual Primary Completion DateDecember 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Volunteers willing and able to be confined to the Clinical Research Unit and comply with study schedule.
  • Women of non-childbearing potential only.
  • Japanese subjects muct have 4 Japanese grandparents who were born in Japan.

Exclusion Criteria:

  • Previous antibiotic use within 14 days prior to dosing.
  • Use of antibiotics during hospitalization within 90 days prior to dosing.
  • History of sensitivity to macrolides or ketolides.
  • Presence of clinically significant eye conditions (other than corrective lenses).
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00793000
Other Study ID Numbers  ICMJE B0581001
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyDirector, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateMay 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now